ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2021
The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Dynamics of anti-SARS-CoV-2 antibodies in the Albanian population: Impact of infection- and vaccine-induced immunity during the COVID-19 pandemic.IJID regions · 2024Article
- Reformulating the susceptible-infectious-removed model in terms of the number of detected cases: well-posedness of the observational model.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022Article
- Malaysian public preferences and decision making for COVID-19 vaccination: A discrete choice experiment.The Lancet regional health. Western Pacific · 2022Article
- COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants.Vaccines · 2022Review
- A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme.Epidemics · 2022Article
- Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2.Vaccines · 2022Article
- Article
- Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.Journal of Crohn's & colitis · 2022Article
- The renewed threat of vaccine-preventable diseases in the war-struck European continent.Germs · 2022Article
- Taking a machine learning approach to optimize prediction of vaccine hesitancy in high income countries.Scientific reports · 2022Article
- Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021.Open forum infectious diseases · 2022Article
- Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China.BMC medicine · 2022Article
- Design and Cross-Cultural Invariance of the COVID-19 Vaccine Conspiracy Beliefs Scale (COVID-VCBS) in 13 Latin American Countries.Frontiers in public health · 2022Article
- Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study.Vaccines · 2021Article
- Energy, environmental, economic and social equity (4E) pressures of COVID-19 vaccination mismanagement: A global perspective.Energy (Oxford, England) · 2021Article
- COVID-19 epidemic and mitigation policies: Positive and normative analyses in a neoclassical growth model.Journal of public economic theory · 2021Article
- Article
- Achieving and sustaining herd immunity to SARS-CoV-2.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021Article
- Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We assess the feasibility of reaching the herd immunity threshold against SARS-CoV-2 through vaccination, considering vaccine effectiveness (VE), transmissibility of the virus and the level of pre-existing immunity in populations, as well as their age structure. If highly transmissible variants of concern become dominant in areas with low levels of naturally-acquired immunity and/or in populations with large proportions of < 15 year-olds, control of infection without non-pharmaceutical interventions may only be possible with a VE ≥ 80%, and coverage extended to children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.